Bausch + Lomb Overhauls Board as Parent Firm Tightens Control
Event summary
- Bausch + Lomb replaces four board members at Bausch Health’s request, effective August 5, 2026.
- New directors include Thomas J. Appio (CEO of Bausch Health), Robert Chersi, Laurence Paul, MD, and Barbara Trebbi.
- Q2 2026 revenue hits $1.394 billion, up 9% year-over-year, with double-digit growth in Surgical and Pharmaceuticals segments.
- Adjusted cash flow from operations more than triples to $161 million in Q2 2026.
- Company reaffirms full-year 2026 guidance of $5.44B–$5.54B revenue and $1.025B–$1.075B adjusted EBITDA.
The big picture
Bausch Health’s move to replace nearly half of Bausch + Lomb’s board signals a tighter grip on the publicly traded subsidiary, potentially reshaping strategic direction. The governance shift comes amid strong Q2 results, with broad-based growth across segments and significant margin expansion. The company’s focus on innovation in dry eye disease, surgical technologies, and AI reflects broader industry trends toward digital health integration and aging population needs.
What we're watching
- Governance Dynamics
- How Bausch Health’s increased influence over Bausch + Lomb’s board may impact strategic independence and operational focus.
- Execution Risk
- Whether the company can sustain its strong Q2 performance amid broader market challenges in eye health.
- Pipeline Development
- The pace at which Bausch + Lomb advances its diversified pipeline, particularly in AI and computational biology.
Related topics